logo
logo

Meta Pharmaceuticals, A Pioneer Biotech In Immune-Metabolism, Raised 15M Usd To Accelerate Its Pipeline Development

Jun 13, 2022•about 3 years ago
Shenzhen

Description

Today, META Pharmaceuticals, China's first immunometabolism-based small-molecule drug discovery company, announced two consecutive Seed and Pre-A funding rounds totaling 15 million USD. Investors include Forcefield Ventures, XtalPi Inc., IMO Ventures, and Tiantu Capital. In combining cutting-edge discoveries in immunometabolism and artificial intelligence (AI), META Pharmaceuticals has built an AI-powered metabolic target discovery platform and aims to develop the next generation of safer and more effective autoimmune disease medicines based on new biological mechanisms.

Company Information

Company

Meta Pharmaceuticals

Location

Shenzhen, Guangdong Province, China

About

Meta Pharmaceuticals Inc. is an innovative drug discovery company focused on autoimmune diseases. The name META derives from the word metabolism and symbolizes the company's focus on the emerging cross-disciplinary field between metabolism and immunology to address the unmet needs of patients worldwide. Founded by a team of biomedical doctors from Weil Cornell Medicine and Memorial Sloan Kettering Cancer Center, META Pharmaceuticals is incubated by Forcefield Ventures and XtalPi, a leading AI-powered drug R&D platform company. Based on cutting-edge biology theories, META Pharmaceuticals has identified a series of autoimmune disease targets that can safely and effectively regulate immune system functions by manipulating the vitality of cellular metabolism. META Pharmaceuticals is partnering with XtalPi to develop these targets into first-in-class therapeutics. Through the fusion of fundamental science, AI, and fast experimental validation, this collaboration leverages AI + biomedical research to create a fast and reliable analytic and validation loop for new therapeutic targets and their mechanisms of action, accelerating target discovery and their translation into new therapeutics.